Recurrent Respiratory Papillomatosis and Bevacizumab Treatment/Reply

In a retrospective analysis, Rahbar and colleagues demonstrated high expression of VEGFR (VEGF receptor)-1 and VEGFR-2 mRNAs in subepithelial blood vessels of patients with recurrent respiratory papillomatosis (RRP) (2). Role of vascular endothelial growth factor-A in recurrent respiratory papilloma...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2018-02, Vol.197 (4), p.539-542
Main Authors: Fernandez-Bussy, Sebastian, Labarca, Gonzalo, Vial, Macarena R, Soto, Rodrigo, Mehta, Hiren J, Jantz, Michael, Majid, Adnan, Burotto, Mauricio, Kalanjeri, Satish, Hoffman, Steve, Farver, Carol, Almeida, Francisco Aécio
Format: Article
Language:English
Subjects:
Copyright
Data analysis
Human papillomavirus
Immunotherapy
Monoclonal antibodies
Patients
Vascular endothelial growth factor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a retrospective analysis, Rahbar and colleagues demonstrated high expression of VEGFR (VEGF receptor)-1 and VEGFR-2 mRNAs in subepithelial blood vessels of patients with recurrent respiratory papillomatosis (RRP) (2). Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. From the Authors: We thank Dr. Fernandez-Bussy and colleagues for their comments in response to our article (1), and for sharing their experience with systemic bevacizumab for recurrent respiratory papillomatosis (RRP).
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201702-0279LE